2027 Healthcare Provider Leads 
Impetus Digital
MARCH 15, 2024
In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers (2).
PM360
JULY 13, 2023
Patients now demand greater access to their health information, desire more communication with their healthcare providers, and seek personalized care tailored to their individual needs. Patients increasingly expect a seamless healthcare experience in which all their health information is integrated and easily accessible.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medico Reach
SEPTEMBER 19, 2022
However, over 95% of healthcare providers use this technology after the global viral outbreak. Adopting this technology can offer numerous benefits to healthcare companies and professionals. Hence, organizations can utilize cost savings to plan more effective healthcare marketing campaigns. Benefits of Telehealth.
LEVO Health
JULY 15, 2024
billion by 2027. This growth presents a significant opportunity for healthcare organizations and businesses, but it also means the market is becoming increasingly saturated. Given their effectiveness, GLP-1 medications have gained popularity, leading to a surge in market demand. In 2021, the GLP-1 market was valued at $16.53
PM360
JUNE 29, 2022
What if you scan a QR code on the box or bottle and it would trigger an approval from your healthcare provider? Healthcare has been expanding beyond the walls of traditional health systems for years, and this change has only been accelerated by COVID-19. Additionally, Walgreens Boots Alliance (WBA) has made a $5.2
Clarivate
SEPTEMBER 5, 2024
1: CMS obtained steep price cuts in its first round of negotiations Source: The Centers for Medicare & Medicaid Services By 2027, 20 additional drugs per year will be negotiated, including often complex and expensive physician-administered Medicare Part B drugs, such as infusible biologics.
PM360
APRIL 7, 2023
However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. It’s amazing we still separate the drug costs from overall healthcare costs,” Sontupe says.
Expert insights. Personalized for you.
79 
Let's personalize your content